third harmonic bio is a clinical-stage company developing a highly selective, oral kit inhibitor for treatment of severe allergy and inflammation. kit is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. our lead product candidate, thb001, is the first highly selective, oral small-molecule kit inhibitor to enter clinical development. with promising drug-like properties and an encouraging early clinical profile, thb001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.
Company profile
Ticker
THRD
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
THB MS, Inc. ...
IRS number
834553503
THRD stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
8-K
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
28 Mar 24
S-8
Registration of securities for employees
26 Mar 24
8-K
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
4 Jan 24
8-K
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Latest ownership filings
4
Natalie C. Holles
15 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
4
Julie Person
8 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
GEOFF MCDONOUGH
28 Mar 24
3
GEOFF MCDONOUGH
28 Mar 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
4
Natalie C. Holles
9 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 274.33 mm | 274.33 mm | 274.33 mm | 274.33 mm | 274.33 mm | 274.33 mm |
Cash burn (monthly) | 1.41 mm | 2.10 mm | 3.62 mm | 3.92 mm | 100.00 k | 606.25 k |
Cash used (since last report) | 9.73 mm | 14.45 mm | 24.89 mm | 27.02 mm | 688.46 k | 4.17 mm |
Cash remaining | 264.60 mm | 259.89 mm | 249.44 mm | 247.31 mm | 273.64 mm | 270.16 mm |
Runway (months of cash) | 187.2 | 123.8 | 69.0 | 63.0 | 2736.4 | 445.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 59 |
Opened positions | 11 |
Closed positions | 3 |
Increased positions | 18 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 241.59 bn |
Total shares | 55.11 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Atlas Venture Life Science Advisors | 10.91 mm | $69.70 bn |
Atlas Venture Fund XI | 10.31 mm | $175.33 mm |
Orbimed Advisors | 5.78 mm | $36.93 bn |
Biotechnology Value Fund L P | 4.37 mm | $18.77 mm |
BVF | 4.37 mm | $27.90 bn |
EcoR1 Capital | 2.98 mm | $19.06 bn |
General Atlantic | 2.96 mm | $18.91 bn |
Novartis Institutes for BioMedical Research | 2.64 mm | $0.00 |
Tang Capital Management | 1.80 mm | $11.50 bn |
Commodore Capital | 1.70 mm | $10.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Holles Natalie C. | Common Stock | Sell | Dispose S | No | Yes | 12.1857 | 13,558 | 165.21 k | 1,218,836 |
11 Apr 24 | Holles Natalie C. | Common Stock | Option exercise | Acquire M | No | No | 4.2 | 13,558 | 56.94 k | 1,232,394 |
11 Apr 24 | Holles Natalie C. | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.2 | 13,558 | 56.94 k | 454,076 |
4 Apr 24 | Julie Person | Common Stock | Sell | Dispose S | No | Yes | 10 | 1,107 | 11.07 k | 0 |
4 Apr 24 | Julie Person | Common Stock | Option exercise | Acquire M | No | No | 4.2 | 1,107 | 4.65 k | 1,107 |
4 Apr 24 | Julie Person | Employee Option Grant Common Stock | Option exercise | Dispose M | No | No | 4.2 | 1,107 | 4.65 k | 175,962 |
27 Mar 24 | Mcdonough Geoff | Stock Option Common Stock | Grant | Acquire A | No | No | 9.47 | 60,000 | 568.20 k | 60,000 |
5 Jan 24 | Christopher M. Murphy | Employee Option Grant Common Stock | Grant | Acquire A | No | No | 10.89 | 410,000 | 4.46 mm | 410,000 |
Press releases
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
28 Mar 24
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)
22 Feb 24